Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11357-020-00261-6 http://scihub22266oqcxt.onion/10.1007/s11357-020-00261-6 32902818!7479299!32902818     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Geroscience 2021 ; 43 (3): 1093-1112 Nephropedia Template TP {{tp|p=32902818|t=2021. A geroscience perspective on immune resilience and infectious diseases: a potential case for metformin |pdf=|usr=}}{{32902818}} gab.com Text A geroscience perspective on immune resilience and infectious diseases: a potential case for metformin JO: Geroscience http://www.kidney.de/pget.php?&tw=1&pmid=32902818 #FOAvip We are in the midst of the global pandemic. Though acute respiratory coronavirus (SARS-COV2) that leads to COVID-19 infects people of all ages, severe symptoms and mortality occur disproportionately in older adults. Geroscience interventions that target biological aging could decrease risk across multiple age-related diseases and improve outcomes in response to infectious disease. This offers hope for a new host-directed therapeutic approach that could (i) improve outcomes following exposure or shorten treatment regimens; (ii) reduce the chronic pathology associated with the infectious disease and subsequent comorbidity, frailty, and disability; and (iii) promote development of immunological memory that protects against relapse or improves response to vaccination. We review the possibility of this approach by examining available evidence in metformin: a generic drug with a proven safety record that will be used in a large-scale multicenter clinical trial. Though rigorous translational research and clinical trials are needed to test this empirically, metformin may improve host immune defenses and confer protection against long-term health consequences of infectious disease, age-related chronic diseases, and geriatric syndromes. Twit Text FOAVip A geroscience perspective on immune resilience and infectious diseases: a potential case for metformin ????Geroscience http://www.kidney.de/pget.php?&tw=1&pmid=32902818 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32902818 #FOAvip English Wikipedia <ref>{{Cite pmid|32902818}}</ref> A geroscience perspective on immune resilience and infectious diseases: a potential case for metformin #MMPMID32902818 Justice JN; Gubbi S; Kulkarni AS; Bartley JM; Kuchel GA; Barzilai N Geroscience 2021[Jun]; 43 (3): 1093-1112 PMID32902818show ga We are in the midst of the global pandemic. Though acute respiratory coronavirus (SARS-COV2) that leads to COVID-19 infects people of all ages, severe symptoms and mortality occur disproportionately in older adults. Geroscience interventions that target biological aging could decrease risk across multiple age-related diseases and improve outcomes in response to infectious disease. This offers hope for a new host-directed therapeutic approach that could (i) improve outcomes following exposure or shorten treatment regimens; (ii) reduce the chronic pathology associated with the infectious disease and subsequent comorbidity, frailty, and disability; and (iii) promote development of immunological memory that protects against relapse or improves response to vaccination. We review the possibility of this approach by examining available evidence in metformin: a generic drug with a proven safety record that will be used in a large-scale multicenter clinical trial. Though rigorous translational research and clinical trials are needed to test this empirically, metformin may improve host immune defenses and confer protection against long-term health consequences of infectious disease, age-related chronic diseases, and geriatric syndromes. |*COVID-19[MESH] |*Communicable Diseases/drug therapy[MESH] |*Metformin/therapeutic use[MESH] |Aged[MESH] |Humans[MESH] |Multicenter Studies as Topic[MESH] |RNA, Viral[MESH]A geroscience perspective on immune resilience and infectious diseases(epmc).pdf DeepDyve Pubget Overpricing